Journal Article

Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2)

Dirckx, Maaike, Mangnus, Thomas J. P., Redekop, Ken, Baart, Sara J., Dik, Willem A., Huygen, Frank J. P. M., de Vos, Cecile C., Siepman, Theodora A. M., Bharwani, Krishna D.

2023

Overview

Background Complex regional pain syndrome (CRPS) is a chronic pain condition of an extremity. While achieving pain relief in CRPS is challenging, esketamine infusions can accomplish pain relief for several weeks post-infusion in a subgroup of CRPS patients. Unfortunately, CRPS esketamine protocols are very heterogeneous in advice on dosage, administration and treatment setting. Currently, no trials are available that study differences between intermittent and continuous esketamine infusions for CRPS. With the current situation of bed shortages, it is difficult to admit patients for several consecutive days for inpatient esketamine treatments. In this study, we investigate whether 6 intermittent outpatient esketamine treatments are not inferior to a continuous 6-day inpatient esketamine treatment in establishing pain relief. In addition, several secondary study parameters will be assessed in order to investigate mechanisms responsible for pain relief by esketamine infusions. Furthermore, the cost-effectiveness will be analyzed. Methods In this RCT, the primary objective is to demonstrate that an intermittent esketamine dosing regimen is non-inferior to a continuous esketamine dosing regimen at 3 months follow-up. We will include 60 adult CRPS patients. The inpatient treatment group receives a continuous intravenous esketamine infusion for 6 consecutive days. The outpatient treatment group receives a 6-hour intravenous esketamine infusion every 2 weeks for 3 months. Esketamine dose will be individually tailored and is started at 0.05 mg/kg/h and can be increased to a maximum of 0.2 mg/kg/h. Each patient will be followed for 6 months. The primary study parameter is perceived pain intensity, measured by an 11-point Numerical Rating Scale. Secondary study parameters are conditioned pain modulation, quantitative sensory testing, adverse events, thermography, blood inflammatory parameter, questionnaires about functionality, quality of life and mood and costs per patient. Discussion If our study reveals non-inferiority between intermittent and continuous esketamine infusions, these findings can be beneficial to increase the availability and flexibility of esketamine infusions through outpatient treatments. Furthermore, the costs of outpatient esketamine infusions could be lower than inpatient esketamine infusions. In addition, secondary parameters may predict response to esketamine treatment. Trial registration ClinicalTrials.gov Identifier NCT05212571 , date of registration 01-28-2022. Protocol version: Version 3, February 2022.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adult / Analgesics / Analysis / Antidepressants / Care and treatment / Chronic pain / Chronic Pain - therapy / Clinical trials / Complex regional pain syndrome / Complex Regional Pain Syndromes - chemically induced / Complex Regional Pain Syndromes - diagnosis / Complex Regional Pain Syndromes - drug therapy / Contraindications / CRPS / Diagnosis / Dosage / Drug dosages / Drug therapy / Epidemiology / Equivalence Trials as Topic / Esketamine / Health aspects / Hospitals / Humans / Inflammation / Informed consent / Inpatient / Internal Medicine / Intervention / Intravenous administration / Ketamine / Ketamine - adverse effects / Medical ethics / Medical research / Medicine / Medicine & Public Health / Orthopedics / Outpatient / Pain / Pandemics / Patients / Physiology, Pathological / Quality of Life / Randomized Controlled Trials as Topic / Rehabilitation / Rheumatology / Sports Medicine / Study Protocol / Thermography